Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care versus celecoxib outcome trial (SCOT)

Susanne Perez-Gutthann; T. MacDonald; I. Mackenzie; L. Wei; C. Hawkey; I. Ford; J Hallas; J. Webster; D. Reid; S Ralston; M Walters; R. Hobbs; Sir L. Ritchie; M Davis; Susanne Perez-Gutthann; F. Ruschitzka; J Scheiman; E. Findlay; J. McMurray; B. Delaney; D. Grobbee; S. Kean; N. Greenlaw; M Robertson; K Fox; G. Murray; P. Jhund; M. Petrie; J. Dillon; J Moeller; A. Lanas

Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care versus celecoxib outcome trial (SCOT)

MacDonald, T., Mackenzie, I., Wei, L., Hawkey, C., Ford, I., Hallas, J., Webster, J., Reid, D., Ralston, S., Walters, M., Hobbs, R., Ritchie, S. L., Davis, M., Perez-Gutthann, S., Ruschitzka, F., Scheiman, J., Findlay, E., McMurray, J., Delaney, B., ... Lanas, A. (2013). Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care versus celecoxib outcome trial (SCOT). British Medical Journal, 3.

Copy citation